FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     WITTE OWEN N.				2. Issuer Name and Ticker or Trading Symbol Allogene Therapeutics, Inc. [ ALLO ]							elationship o	able)	Perso	on(s) to Issu			
(Last)				3. Date of Earliest Transaction (Month/Day/Year) 06/05/2024							Officer ( below)	give title		Other (s below)	pecify		
210 EAST GRAND AVENUE			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SOUTH FRANCI		A	94080									N	Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)	R	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a the affirmative defense conditions of Rule 10b5-1(c). See Instruction					nt to a contraduction 10.	contract, instruction or written plan that is intended to satisfy 10.						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				2. Transactio Date Month/Day/	Execution Date		Date,	Transaction Disposed Code (Instr.			ities Acquired (A) or d Of (D) (Instr. 3, 4 and 5		Beneficia Owned Fo	For lly (D) ollowing (I) (		Direct I Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership
								Code	/ An	Amount (A) or (D)		r Price		nsaction(s) str. 3 and 4)			(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative Conversion Date Execut Security or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date if any (Month/Day/Yea	Code (	saction e (Instr. Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e E s ( I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable	Expira Date		Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to buy)	\$2.44	06/05/2024		A		191,082		(1)	06/05/	5/2034	Common Stock	191,082	\$0	191,08	32	D	

## **Explanation of Responses:**

1. Vesting in 12 equal monthly installments

## Remarks:

/s/Owen Witte

06/07/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.